Upregulation of the healthy SCN1A allele using oligonucleotide-based compounds (AntagoNATs) to target SCN1ANAT in a knock-in mouse model of DS and in a non-human primate led to significant improvements in seizure phenotype in the animals (84). The gene discussed is SCN1A; the disease is Dravet syndrome.